Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CLDX
Celldex Therapeutics, Inc
stock NASDAQ

At Close
Jan 21, 2026 3:59:48 PM EST
26.17USD+4.097%(+1.03)367,233
26.16Bid   26.19Ask   0.03Spread
Pre-market
Jan 21, 2026 8:23:30 AM EST
25.14USD0.000%(0.00)1,550
After-hours
Jan 21, 2026 4:00:30 PM EST
26.17USD0.000%(0.00)7,229
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 8, 2021
08:03AM EST  Celldex Announces First Patient Dosed In Phase 1 Study Of CDX-0159 In Prurigo Nodularis   Benzinga
08:01AM EST  Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159   GlobeNewswire Inc
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:00AM EST  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Companys bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data were presented in a poster session as part of the Society for Immunotherapy of Cancers 36th Annual Meeting (SITC 2021).   GlobeNewswire Inc
Nov 11, 2021
07:01AM EST  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November:   GlobeNewswire Inc
Nov 9, 2021
04:22PM EST  Celldex Therapeutics Q3 EPS $(0.45) Down From $(0.36) YoY, Sales $153.00K Down From $668.00K YoY   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
12:00AM EDT  - Rapid and sustained improvement in urticaria control after single dose of CDX-0159 -- Greatly improved patient quality of life and reduced disease impact -- Data further support 95% complete response rate to provocation testing -   GlobeNewswire Inc
Sep 24, 2021
07:01AM EDT  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 1:20 p.m. ET.   GlobeNewswire Inc
Sep 23, 2021
08:04AM EDT  Celldex To Present CDX-0159 Phase 1b Results In Inducible Urticaria At 2021 European Academy Of Dermatology And Venereology 30th Congress Sept. 29   Benzinga
08:01AM EDT  Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b   GlobeNewswire Inc
Sep 17, 2021
12:06PM EDT  Where Celldex Therapeutics Stands With Analysts   Benzinga
10:14AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 17, 2021   Benzinga
08:24AM EDT  Jefferies Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $66   Benzinga
Sep 13, 2021
12:45PM EDT  HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $60   Benzinga
09:13AM EDT  Celldex Announces Initiation Of CDX-0159 Subcutaneous Formulation Study   Benzinga
09:01AM EDT  Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation   GlobeNewswire Inc
Sep 10, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021   Benzinga
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
07:33AM EDT  SVB Leerink Initiates Coverage On Celldex Therapeutics with Outperform Rating, Announces Price Target of $68   Benzinga
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 25, 2021
07:30AM EDT  The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
06:12AM EDT  HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $54   Benzinga
Aug 5, 2021
04:32PM EDT  Celldex Therapeutics Q2 EPS $(0.34) Up From $(0.50) YoY, Sales $3.48M Up From $236.00K YoY   Benzinga
Jul 22, 2021
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021   Benzinga
07:42AM EDT  Guggenheim Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $66   Benzinga
Jul 16, 2021
04:01PM EDT  Celldex Therapeutics Announces Closing of Public Offering of   GlobeNewswire Inc
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
06:41AM EDT  Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate   Benzinga
Jul 13, 2021
08:32PM EDT  Celldex Therapeutics Announces Pricing of Upsized $250 Million   GlobeNewswire Inc
08:05AM EDT  The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data   Benzinga
Jul 12, 2021
04:01PM EDT  Celldex Therapeutics Announces Proposed Public Offering Of $175M Shares Of Common Stock   Benzinga
02:31PM EDT  Mid-Afternoon Market Update: Dow Surges Over 100 Points; State Auto Financial Shares Jump   Benzinga
12:24PM EDT  Mid-Day Market Update: Crude Oil Down 1%; Celldex Therapeutics Shares Spike Higher   Benzinga
10:14AM EDT  Stocks That Hit 52-Week Highs On Monday   Benzinga
10:07AM EDT  Shares of Celldex Therapeutics, Inc. (CLDX) are surging over 30% on Monday morning after the biopharmaceutical company reported positive results from an early-stage study of a skin disease.   RTTNews
09:56AM EDT  Celldex Therapeutics Shares See Volume; Cantor Raises Price Target From $35 To $61   Benzinga
09:54AM EDT  Celldex Therapeutics Shares See Volume; Hearing Cantor Raises Price Target From $35 To $61   Benzinga
07:54AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:12AM EDT  Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159   Benzinga
06:09AM EDT  HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $50   Benzinga
Jul 9, 2021
06:01PM EDT  Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b   GlobeNewswire Inc
Jul 6, 2021
03:55PM EDT  Celldex Therapeutics Option Alert: Jul 16 $35 Calls Sweep (30) near the Ask: 248 @ $2.4 vs 85 OI; Earnings 8/5 After Close [est] Ref=$31.35   Benzinga
Jun 30, 2021
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
Jun 29, 2021
08:17AM EDT  The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout   Benzinga
Jun 4, 2021
09:17AM EDT  Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting   Benzinga
09:01AM EDT  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Companys Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. These data were presented in a poster session as part of the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting taking place June 4-8, 2021.   GlobeNewswire Inc
Jun 1, 2021
07:33AM EDT  Celldex Therapeutics To Present Abstract From Phase 1B Study Of CDX-0159 At European Academy Of Allergy And Clinical Immunology Annual Congress 2021 Jul. 10   Benzinga
07:31AM EDT  Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b   GlobeNewswire Inc
May 26, 2021
04:01PM EDT  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30 p.m. ET.   GlobeNewswire Inc
May 6, 2021
04:38PM EDT  Celldex Therapeutics Q1 EPS $(0.42) Up From $(0.73) YoY, Sales $685.00K Down From $2.73M YoY   Benzinga
Apr 30, 2021
07:31AM EDT  The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs   Benzinga
Apr 29, 2021
08:15AM EDT  The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx   Benzinga
Apr 28, 2021
07:26AM EDT  The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping   Benzinga
Apr 12, 2021
04:01PM EDT  Celldex Presents Data From ILT4/PD-(L)1 Bispecific Antibody Program At AACR 2021   Benzinga
04:01PM EDT  Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific   GlobeNewswire Inc
Mar 29, 2021
04:02PM EDT  Celldex Therapeutics Q4 EPS $(0.55) Up From $(0.64) YoY, Sales $3.80M Up From $887.00K YoY   Benzinga
04:01PM EDT  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020.   GlobeNewswire Inc
02:34PM EDT  Mid-Afternoon Market Update: Dow Rises 50 Points; Orphazyme Shares Plunge   Benzinga
12:11PM EDT  Mid-Day Market Update: Gold Drops Over 1%; Humanigen Shares Spike Higher   Benzinga
10:11AM EDT  Mid-Morning Market Update: Markets Mostly Lower; Cal-Maine Foods Reports Mixed Q3 Results   Benzinga
07:36AM EDT  Celldex's CDX-0159 Shows 80% Response Rate In Early-Stage Skin Allergy Study   Benzinga
06:41AM EDT  Celldex Reports 80% CR Rate In Interim Data Update From Phase 1b Study Of CDX-0159 In Chronic Inducible Urticaria   RTTNews
06:32AM EDT  Celldex Reports 80% Complete Response Rate and Generally Well Tolerated in Phase 1b study of CDX-0159 in Chronic Inducible Urticaria   Benzinga
06:30AM EDT  --CDX-0159 generally well tolerated to date---Conference call to be held at 7:45 a.m. ET today--   GlobeNewswire Inc
Mar 27, 2021
01:01PM EDT  The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week   Benzinga
Mar 5, 2021
01:00PM EST  Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Companys participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The presentation for the virtual conference was prerecorded and will be accessible to conference attendees starting on Tuesday, March 9th2021 at 7:00 a.m. ET.   GlobeNewswire Inc
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
Feb 23, 2021
07:25AM EST  The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts   Benzinga
07:06AM EST  HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $36   Benzinga
06:02AM EST  Celldex Therapeutics To Test CDX-0159 In Chronic Itchy Skin Disorder   Benzinga
Feb 22, 2021
04:09PM EST  Celldex Therapeutics Reports Expansion Of Development Of CDX-0159 Into Prurigo Nodularis   Benzinga
04:01PM EST  --Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation---Potential to expand future CDX-0159 development beyond chronic urticarias to chronic pruritic diseases and other significant indications driven by itch and neuroinflammation--   GlobeNewswire Inc
08:01AM EST  Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. ET.   GlobeNewswire Inc
Feb 19, 2021
07:25AM EST  The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko   Benzinga
Feb 18, 2021
08:14AM EST  The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Jan 4, 2021
08:23AM EST  Celldex Appoints Freddy Jimenez SVP And General Counsel   RTTNews
08:01AM EST  Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President   GlobeNewswire Inc
Dec 16, 2020
10:00AM EST  10 Healthcare Stocks That Thrived In 2020   Benzinga
Dec 9, 2020
08:02AM EST  Celldex Doses First Patient In Phase 1b Study Of CDX-0159 In Chronic Inducible Urticaria   Benzinga
08:01AM EST  Celldex Doses First Patient in Phase 1b Study of CDX-0159 in   GlobeNewswire Inc
Nov 30, 2020
04:01PM EST  Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 pm ET.   GlobeNewswire Inc
Nov 25, 2020
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 9, 2020
08:56AM EST  Celldex Therapeutics Highlights Will Present Data On Its Oncology Portfolio At Society For Immunotherapy Of Cancer Meeting; 'Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated'   Benzinga
08:01AM EST  --Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated---Axl and CDX-527 programs highlighted--   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
04:24PM EST  Celldex Therapeutics Q3 EPS $(0.36) Up From $(0.75) YoY, Sales $668.00K Up From $546.00K YoY   Benzinga
Oct 19, 2020
08:25AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:17AM EDT  HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $25   Benzinga
Oct 13, 2020
08:35AM EDT  Celldex Therapeutics Inc. (CLDX) said Tuesday that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU).   RTTNews
08:17AM EDT  Celldex Says First Patient Dosed In Randomized, Double-blind Phase 1b Study Of CDX-0159   RTTNews
08:01AM EDT  Celldex Therapeutics Reports Initiation Of Phase 1b Study Of CDX-0159 In Chronic Spontaneous Urticaria   Benzinga
08:01AM EDT  Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in   GlobeNewswire Inc
Sep 28, 2020
10:45AM EDT  Shares of Celldex Therapeutics, Inc. (CLDX) are rising more than 20 percent or $2.59 in Monday's morning trade at $15.39, after touching a new 52-week high of $15.65 earlier despite no specific news that could influence the stock.   RTTNews
Sep 10, 2020
04:01PM EDT  Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare Conference and the HC Wainwright & CO 22nd Annual Global Investment Virtual Conference. Presentation details are as follows:   GlobeNewswire Inc
Aug 24, 2020
08:03AM EDT  Celldex Therapeutics Initiates Phase 1 Study Of New Bispecific Product Candidate CDX-527 In Solid Tumors   Benzinga
08:01AM EDT  Celldex Therapeutics Initiates Phase 1 Study of New Bispecific   GlobeNewswire Inc
Aug 6, 2020
04:09PM EDT  Celldex Therapeutics Q2 EPS $(0.50) Beats $(0.58) Estimate, Sales $236.00K May Not Compare To $800.00K Estimate   Benzinga
Aug 3, 2020
08:01AM EDT  Celldex to Report Second Quarter 2020 Financial Results and Host   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC